Complete ADAMTS13 remission in a patient with refractory autoimmune-mediated thrombotic thrombocytopenic purpura after infliximab-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Complete ADAMTS13 remission in a patient with refractory autoimmune-mediated thrombotic thrombocytopenic purpura after infliximab

Published:2021-12 Issue:6 Volume:60 Page:103213
ISSN:1473-0502
Container-title:Transfusion and Apheresis Science
language:en
Short-container-title:Transfusion and Apheresis Science

Author:

Bavli Natalie^ORCID,Lee Nicholas^ORCID,Sarode Ravi,Burstein Ezra^ORCID,Rambally Siayareh

Publisher

Elsevier BV

Subject

Hematology

Reference13 articles.

1. Thrombotic thrombocytopenic purpura;Joly;Blood,2017

2. Survival and relapse in patients with thrombotic thrombocytopenic purpura;Kremer Hovinga;Blood,2010

3. Longitudinal assessments of plasma ADAMTS13 biomarkers predict recurrence of immune thrombotic thrombocytopenic purpura;Sui;Blood Adv,2019

4. Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura;Hie;Blood,2014

5. Redefining outcomes in immune TTP: an international working group consensus report;Cuker;Blood,2021

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Plasma cell‐directed therapy strategies in immune‐mediated thrombotic thrombocytopenic purpura (iTTP);Transfusion;2024-01-18

2. Bortezomib in relapsed/refractory immune thrombotic thrombocytopenic purpura: A single‐centre retrospective cohort and systematic literature review;British Journal of Haematology;2023-08-12

3. Plasma Cell Directed Therapy for Immune Thrombotic Thrombocytopenic Purpura (iTTP);Transfusion Medicine Reviews;2022-10

4. Bortezomib, a promising alternative for patients with refractory or relapsed thrombotic thrombocytopenic purpura after rituximab treatment;British Journal of Haematology;2022-09-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3